Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill tasks HHS with maintaining and publishing an Essential Medicines List and requires regular risk assessments of supply chains for those medicines. It directs HHS to map pharmaceutical supply chains using data analytics, coordinate interagency information sharing, and report findings to Congress.
Transparency versus trade-secret protections
Relative to its intended legislative type, this bill establishes a clear administrative framework requiring HHS (with DoD and other agencies) to maintain an Essential Medicines List, perform a specified supply-chain risk assessment, build/coordinate a mapping effort using data analytics, and provide recurring reports to Congress.
The bill tasks HHS with maintaining and publishing an Essential Medicines List and requires regular risk assessments of supply chains for those medicines.
It directs HHS to map pharmaceutical supply chains using data analytics, coordinate interagency information sharing, and report findings to Congress.
The Department of Defense must biannually report drugs it purchased that contain materials or finished products sourced from the People’s Republic of China.
Relatively narrow, bipartisan, low‑controversy technical bill; success hinges on funding, industry cooperation, and legislative calendar.
Relative to its intended legislative type, this bill establishes a clear administrative framework requiring HHS (with DoD and other agencies) to maintain an Essential Medicines List, perform a specified supply-chain risk assessment, build/coordinate a mapping effort using data analytics, and provide recurring reports to Congress. It is specific in required outputs, timelines, and report recipients and integrates with several existing statutes.
Transparency versus trade-secret protections
These are examples from the analysis, not a ranked list of the most-affected groups.
Transparency versus trade-secret protections
Likely supportive of stronger supply-chain oversight and transparency to protect public health and preparedness.
Would view risk assessments and mapping as useful tools to prevent shortages and prioritize domestic resilience.
May worry the bill lacks direct funding for domestic manufacturing and equitable access measures.
Generally favorable as a pragmatic, evidence-building measure to reduce supply vulnerabilities.
Appreciates clear timelines, interagency coordination, and analytic approaches, while concerned about costs and possible duplication.
Will want clarity on funding, data sources, and oversight to ensure efficiency.
May cautiously support the national-security aspects, especially the focus on China-linked sourcing and DoD readiness.
However, skeptical about expanding HHS data collection and potentially increasing regulatory burdens on private industry.
Worried about federal overreach, trade-secret exposure, and new compliance costs.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Relatively narrow, bipartisan, low‑controversy technical bill; success hinges on funding, industry cooperation, and legislative calendar.
The bill has not accumulated any surfaced votes yet.
Transparency versus trade-secret protections
Relatively narrow, bipartisan, low‑controversy technical bill; success hinges on funding, industry cooperation, and legislative calendar.
Relative to its intended legislative type, this bill establishes a clear administrative framework requiring HHS (with DoD and other agencies) to maintain an Essential Medicines List, perform a specified supply-chain ris…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.